Claims
- 1. A chemical compound selected from the group consisting of a compound having the formula ##STR58## and the pharmaceutically acceptable acid addition salts thereof, wherein: Ar.sup.1 and Ar.sup.2 are each independently selected from the group consisting of phenyl, substituted phenyl and pyridinyl, wherein said substituted phenyl is phenyl having from 1 to 2 substituents independently selected from the group consisting of halo, lower alkyl, lower alkyloxy, trifluoromethyl and nitro;
- n is an integer of from 2 to 6 inclusive, provided that when C.sub.n H.sub.2n represents a branched alkylene chain, then at least 2 carbon atoms are present in the linear portion of the chain linking
- B with the piperazine nitrogen atom; and
- B is: a radical having the formula ##STR59## wherein: R.sup.1 and R.sup.2 are each independently selected from the group consisting of hydrogen, halo, lower alkyl and trifluoromethyl; and
- Y is a member selected from the group consisting of oxygen, sulfur and a substituted nitrogen of the formula >N-L wherein said L is a member selected from the group consisting of hydrogen, lower alkyl, lower alkylcarbonyl, lower alkyloxycarbonyl-lower alkyl, carboxy-lower alkyl, phenyl, phenylmethyl, lower alkylaminocarbonyl, hydroxymethyl, and lower alkenyl.
- 2. A chemical compound selected from the group consisting of 1-{3-[4-(diphenylmethyl)-1-piperazinyl]propyl}-1,3-dihydro-2H-benzimidazol-2-one and the pharmaceutically acceptable acid addition salts thereof.
- 3. A chemical compound selected from the group consisting of 1-[3-{4-[bis(4-fluorophenyl)methyl]-1-piperazinyl}-propyl]-1,3-dihydro-2H-benzimidazol-2-one and the pharmaceutically acceptable acid addition salts thereof.
- 4. A chemical compound selected from the group consisting of 1-[4-{4-[bis(4-fluorophenyl)methyl]-1-piperazinyl}butyl]-1,3-dihydro-2H-benzimidazol-2-one and the pharmaceutically acceptable acid addition salts thereof.
- 5. A chemical compound selected from the group consisting of 1-{4-[4-(diphenylmethyl)-1-piperazinyl]butyl}-1,3-dihydro-2H-benzimidazol-2-one and the pharmaceutically acceptable acid addition salts thereof.
- 6. The chemical compound of claim 1 wherein Y is a substituted nitrogen of the formula >N--L.
- 7. A pharmaceutical composition comprising an inert carrier material and as an active ingredient an effective antihistaminic or anti-anaphylactic amount of a chemical compound selected from the group consisting of a compound having the formula ##STR60## and the pharmaceutically acceptable acid addition salts thereof, wherein: Ar.sup.1 and Ar.sup.2 are each independently selected from the group consisting of phenyl, substituted phenyl and pyridinyl, wherein said substituted phenyl is phenyl having from 1 to 2 substituents independently selected from the group consisting of halo, lower alkyl, lower alkyloxy, trifluoromethyl and nitro;
- n is an integer of from 2 to 6 inclusive, provided that when C.sub.n H.sub.2n represents a branched alkylene chain, then at least 2 carbon atoms are present in the linear portion of the chain linking B with the piperazine nitrogen atom; and
- B is: a radical having the formula ##STR61## wherein: R.sup.1 and R.sup.2 are each independently selected from the group consisting of hydrogen, halo, lower alkyl and trifluoromethyl; and
- Y is a member selected from the group consisting of oxygen, sulfur and a substituted nitrogen of the formula >N--L wherein said L is a member selected from the group consisting of hydrogen, lower alkyl, lower alkylcarbonyl, lower alkyloxycarbonyl-lower alkyl, carboxy-lower alkyl, phenyl, phenylmethyl, lower alkylaminocarbonyl, hydroxymethyl, and lower alkenyl.
- 8. A pharmaceutical composition comprising an inert carrier material and as an active ingredient an effective antihistaminic or anti-anaphyylactic amount of a compound selected from the group consisting of 1-{3-[4-(diphenylmethyl)-1-piperazinyl]propyl}-1,3-dihydro-2H-benzimidazol-2-one and the pharmaceutically acceptable acid addition salts thereof.
CROSS-REFERENCE TO RELATED APPLICATIONS
This is a division of application Ser. No. 875,342, filed Feb. 6, 1978, which is a continuation of abandoned application Ser. No. 753,062 filed Dec. 21, 1976, which is a continuation-in-part of abandoned application, Ser. No. 672,919, filed Apr. 2, 1976.
US Referenced Citations (5)
Divisions (1)
|
Number |
Date |
Country |
Parent |
875342 |
Feb 1978 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
753062 |
Dec 1976 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
672919 |
Apr 1976 |
|